Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICONIC
2024-517378-22-00Phase 2Authorised
- Sponsor
- Fondazione Centro Nazionale di Adroterapia Oncologica
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, atezolizumab, nivolumab and cemiplimab in melanoma, transitional cell carcinoma (TCC), non-small cell lung cancer (NSCLC) and 1 more, sponsored by Fondazione Centro Nazionale di Adroterapia Oncologica. Primary endpoints: Objective response rate (ORR) according to RECIST and Toxicity according to CTCAE v5.0. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
melanomatransitional cell carcinoma (TCC)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-517378-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517378-22-00.